All patients have completed AcuCort's phase IV study ZEQ001
AcuCort's Phase IV study, ZEQ001, began in late January 2024. This study enrolled 50 patients, and the last participant has now completed it. The study findings are intended to be published in scientific journals, providing key support for AcuCort's upcoming launch initiatives.
“Our Phase IV study, ZEQ001, marks a significant milestone for AcuCort and the scientific foundation for Zeqmelit®. The study offers valuable insights into patients’ experiences and confidence with the medication. We look forward to sharing the scientific findings and are confident that they will provide a vital foundation for both healthcare providers and our partners in their work to improve care for patients suffering from severe allergies,” says AcuCort's CEO, Jonas Jönmark.
A key objective of the study, an open, non-randomised, low-intervention study, is to obtain scientific data from patients who previously used tablets but, in the study, are using Zeqmelit® instead. The study will answer essential questions, such as whether patients feel confident with Zeqmelit®, what the experience of using the medication is like, and whether they carry it with them.
The study results will be published in scientific journals, thereby providing crucial support for the launch of Zeqmelit® in selected markets.
For further information:
Jonas Jönmark, vd, AcuCort AB
Telefon: 070 365 5400
Epost: [email protected]
About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.